Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v14-FR | Version v5-EN | |
|---|---|---|
| Language | French | English |
| Date Updated | 2022-11-03 | 2022-07-07 |
| Drug Identification Number | 02139545 | 02139545 |
| Brand name | POTASSIUM PHOSPHATES INJECTION, USP | POTASSIUM PHOSPHATES INJECTION, USP |
| Common or Proper name | Potassium Phosphates Injection, USP | Potassium Phosphates Injection, USP |
| Company Name | FRESENIUS KABI CANADA LTD | FRESENIUS KABI CANADA LTD |
| Ingredients | POTASSIUM PHOSPHATE DIBASIC POTASSIUM PHOSPHATE MONOBASIC | POTASSIUM PHOSPHATE DIBASIC POTASSIUM PHOSPHATE MONOBASIC |
| Strength(s) | 236MG 224MG | 236MG 224MG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS | INTRAVENOUS INTRAVENOUS |
| Packaging size | 15 mL | 15 mL |
| ATC code | B05XA | B05XA |
| ATC description | I.V. SOLUTION ADDITIVES | I.V. SOLUTION ADDITIVES |
| Reason for shortage | Other (Please describe in comments) | Other (Please describe in comments) |
| Anticipated start date | ||
| Actual start date | 2022-04-01 | 2022-04-01 |
| Estimated end date | 2022-11-23 | Unknown |
| Actual end date | 2022-11-01 | |
| Shortage status | Resolved | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | On 100% allocation. Supply interruption effective September 1, 2022 until November 23, 2022 with coverage available using 50mL format. Please see communication for further details. | Per our communication dated May 6, 2022, allocations for Potassium Phosphates Injection, USP 3 mmol/mL Phosphorus SD Vial 15 mL will be reducing from 100% demand of 15mL plus coverage of 50mL demand at a ratio of 2:1 to only cover 100% demand of 15mL. |
| Health Canada comments |